CompletedPhase 3

A Study of MK-3009 in Japanese Patients With Skin or Blood Stream Infections Caused by Methicillin-resistant Staphylococcus Aureus (MK-3009-002)

122 participantsStarted 2008-09

Plain-language summary

The study investigates the efficacy and safety of MK-3009 in participants with skin infections, septicemia and right-sided infective endocarditis (RIE) caused by methicillin-resistant Staphylococcus aureus (MRSA).

Who can participate

Age range20 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Both Sexes, Aged 20 Years Or Older * Japanese Participants With Skin And Soft Tissue Infections, Septicemia, or RIE Known Or Suspected To Be Caused By MRSA * Written Informed Consent Exclusion Criteria: * Participants With Skin and Soft Tissue infections That Can Be Treated By Surgery Alone * Participants With Pneumonia

What they're measuring

Efficacy Adjudication Committee (EAC) Assessment of Number of Participants With Clinical Success at Test of Cure (TOC)

Timeframe: 7-14 days for SSTI, 14-42 days for septicemia and right-sided infective endocarditis (RIE)

Efficacy Adjudication Committee (EAC) Assessment of Number of Participants With Microbiological Response at TOC

Timeframe: 7-14 days for SSTI, 14-42 days for septicemia and RIE

Trial details

NCT IDNCT00770341

SponsorMerck Sharp & Dohme LLC

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2010-02

Results submitted2011-05-17

View on ClinicalTrials.gov More Staphylococcal Infection trials